Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.

Xiuning Li Hiroshi SakaiEnriqueta FelipRemi VeillonMarina Chiara GarassinoJo Raskin Alexis B Cortot Santiago Viteri Julien MazieresEgbert F SmitMichael ThomasWade T IamsByoung Chul ChoHye Ryun KimJames Chih-Hsin YangYuh-Min ChenJyoti D PatelChristine M Bestvina Keunchil ParkFrank GriesingerMelissa JohnsonMaya GottfriedChristian BritschgiJohn Victor HeymachElif SikogluKarin BerghoffKarl-Maria SchumacherRolf BrunsGordon OttoPaul K Paik

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Tepotinib showed meaningful activity across subgroups by age, prior therapies, and brain metastases, with a manageable safety profile and few treatment discontinuations.

Keyphrases

brain metastases
small cell lung cancer
clinical practice
case report
tyrosine kinase
type diabetes
advanced non small cell lung cancer
metabolic syndrome